Margaix-Muñoz M, Bagán JV, Jiménez Y, Sarrión MG,
Poveda-Roda R. Graft-versus-host
disease affecting oral cavity. A review. J Clin Exp Dent. 2015;7(1):e138-45.
doi:10.4317/jced.51975
http://dx.doi.org/doi:10.4317/jced.51975
------------------------------------------------------------------------------------------------------------------------------
References
|
1. Kuten-Shorrer M, Woo SB, Treister NS. Oral
graft-versus-host disease. Dent Clin North Am. 2014;58:351-68. |
|
|
2. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson
G, Mahendra P, et al. Diagnosis and management of chronic graft-versus-host
disease. Br J Haematol. 2012;158:46-61. |
|
|
3. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson
G, Mahendra P, et al. Diagnosis and management of acute graft-versus-host
disease. Br J Haematol. 2012;158:30-45. |
|
|
4. Jaglowski SM, Devine SM. Graft-versus-host
disease: why have we not made more progress?. Curr Opin Hematol.
2014;21:141-7. |
|
|
5. Paczesny S. Discovery and validation of
graft-versus-host disease biomarkers. Blood. 2013;121:585-94. |
|
|
6. Grauer O, Wolff D,
Bertz H, Greinix H, Kühl JS, Lawitschka A, et al. Neurological
manifestations of chronic graft-versus-host disease after allogeneic
haematopoietic stem cell transplantation: report from the Consensus
Conference on Clinical Practice in chronic graft-versus-host disease. Brain. 2010;133:2852-65. |
|
|
7. Linhares YP, Pavletic S, Gale RP. Chronic GVHD:
Where are we? Where do we want to be? Will immunomodulatory drugs help?. Bone Marrow Transplant.
2013;48:203-9. |
|
|
8. Travnik
R, Beckers M, Wolff D, Holler E, Landthaler M, Karrer S. Graft-versus-Host
Disease (GvHD) - an update : Part 1: Pathophysiology, clinical features and
classification of GvHD. Hautarzt. 2011;62:139-54. |
|
|
9. Elad S, Zeevi I, Or R, Resnick IB, Dray L,
Shapira MY. Validation of the National Institutes of Health (NIH) scale for
oral chronic graft-versus-host disease (cGVHD). Biol Blood Marrow Transplant.
2010;16:62-9. |
|
|
10. Filipovich AH, Weisdorf D, Pavletic S, Socie G,
Wingard JR, Lee SJ, et al. National Institutes of Health consensus
development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and staging working group report.
Biol Blood Marrow Transplant. 2005;11:945-56. |
|
|
11. Demarosi F, Lodi G, Carrassi A, Soligo D,
Sardella A. Oral malignancies following HSCT: graft versus host disease and
other risk factors. Oral
Oncol. 2005;41:865-77. |
|
|
12. Treister NS, Cook EF Jr, Antin J, Lee SJ,
Soiffer R, Woo SB. Clinical evaluation of oral chronic graft-versus-host
disease. Biol Blood Marrow Transplant. 2008;14:110-5. |
|
|
13. Salmasian H, Rohanizadegan M, Banihosseini S, Rahimi
Darabad R, Rabbani-Anari M, Shakiba A, et al. Corticosteroid
regimens for treatment of acute and chronic graft versus host disease (GvHD)
after allogenic stem cell transplantation. Cochrane Database Syst Rev.
2010;20:CD005565. http://dx.doi.org/10.1002/14651858 PMID:
20091579. |
|
|
|
|
|
14. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim
JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: review of
available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2006;101:175-83. |
|
|
15. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ,
Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute
graft-versus-host disease and for chronic graft-versus-host disease according
to National Institutes of Health consensus criteria. Blood. 2011;117:3214-9. |
|
|
|
|
|
16. Ferrara
JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550-61. PMID:20091579 |
|
|
|
|
|
17. Meier JK, Wolff D, Pavletic S, Greinix H, Gosau
M, Bertz H, et al. Oral chronic graft-versus-host disease: report from the
International Consensus Conference on clinical practice in cGVHD. Clin Oral
Investig. 2011;15:127-39. |
|
|
18. Mays JW, Fassil H, Edwards DA, Pavletic SZ,
Bassim CW. Oral chronic graft-versus-host disease: current pathogenesis,
therapy, and research. Oral Dis. 2013;19:327-46. |
|
|
19. Flowers ME, Parker PM, Johnston LJ, Matos AV,
Storer B, Bensinger WI, et al. Comparison of chronic graft-versus-host
disease after transplantation of peripheral blood stem cells versus bone
marrow in allogeneic recipients: long-term follow-up of a randomized trial.
Blood. 2002;100:415-9. |
|
|
20. Dignan FL, Scarisbrick JJ, Cornish J, Clark A,
Amrolia P, Jackson G, et al. Organ-specific management and supportive care in
chronic graft-versus-host disease. Br J Haematol. 2012;158:62-78. |
|
|
21. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic
SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host
disease: National Institutes of Health Consensus Development Project on
Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II.
Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12:31-47. |
|
|
22. de la Rosa García E, Bologna Molina R, Vega
González Tde J. Graft-versus-host disease, an eight case report and
literature review. Med
Oral Patol Oral Cir Bucal. 2006;11:e486-92. |
|
|
|
|
|
23. Imanguli MM, Atkinson JC, Mitchell SA, Avila DN,
Bishop RJ, Cowen EW, et al. Salivary gland involvement in chronic
graft-versus-host disease: prevalence, clinical significance, and
recommendations for evaluation. Biol Blood Marrow Transplant. 2010;16:1362-9. |
|
|
24. Lawitschka A, Ball L, Peters C. Nonpharmacologic
treatment of chronic graft-versus-host disease in children and adolescents.
Biol Blood Marrow Transplant. 2012;18:S74-81. |
|
|
25. Pavletic SZ, Martin P, Lee SJ, Mitchell S,
Jacobsohn D, Cowen EW, et al. Measuring therapeutic response in chronic
graft-versus-host disease: National Institutes of Health Consensus
Development Project on Criteria for Clinical Trials in Chronic
Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol
Blood Marrow Transplant. 2006;12:252-66. |
|
|
26. Inamoto Y, Martin
PJ, Chai X, Jagasia M, Palmer J, Pidala J, et al. Clinical
benefit of response in chronic graft-versus-host disease. Biol Blood Marrow
Transplant. 2012;18:1517-24. |
|
|
27. Pérez-Simón JA,
Encinas C, Silva F, Arcos MJ, Díez-Campelo M, Sánchez-Guijo FM, et al. Prognostic
factors of chronic graft-versus-host disease following allogeneic peripheral
blood stem cell transplantation: the national institutes health scale plus
the type of onset can predict survival rates and the duration of
immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14:1163-71. |
|
|
28. Arora M. Therapy of chronic graft-versus-host
disease. Best Pract Res Clin Haematol. 2008;21:271-9. |
|
|
29. Van
Hoef ME. Towards a rational graft-versus-host disease (GVHD) prophylaxis:
rituximab should not be forgotten. Haematologica. 2013;98:e40-1. |
|
|
|
|
|
30. Gutiérrez-Aguirre
CH, Cantú-Rodríguez OG, Borjas-Almaguer OD, González-Llano O, Jaime-Pérez JC,
Solano-Genesta M, et al. Effectiveness of subcutaneous low-dose alemtuzumab
and rituximab combination therapy for steroid-resistant chronic
graft-versus-host disease. Haematologica.
2012;97:717-22. |
|
|
31. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ,
et al. Weekly rituximab followed by monthly rituximab treatment for
steroid-refractory chronic graft-versus-host disease: results from a prospective,
multicenter, phase II study. Haematologica. 2010;95:1935-42. |
|
|
32. Wang Y, Xu LP, Liu DH, Chen H, Chen YH, Han W,
et al. First-line therapy for chronic graft-versus-host disease that includes
low-dose methotrexate is associated with a high response rate. Biol Blood
Marrow Transplant. 2009;15:505-11. |
|
|
33. Park AR, La HO, Cho BS, Kim SJ, Lee BK, Rhie JY,
et al. Comparison of budesonide and dexamethasone for local treatment of oral
chronic graft-versus-host disease. Am J Health Syst Pharm. 2013;70:1383-91. |
|
|
34. Baird K, Steinberg SM, Grkovic L, Pulanic D,
Cowen EW, Mitchell SA, et al. National Institutes of Health chronic
graft-versus-host disease staging in severely affected patients: organ and
global scoring correlate with established indicators of disease severity and
prognosis. Biol Blood Marrow Transplant. 2013;19:632-9. |
|
|
35. da Fonseca MA, Hong C. An overview of chronic
oral graft-vs-host disease following pediatric hematopoietic stem cell
transplantation. Pediatr
Dent. 2008;30:98-104. |
|
|
36.
Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, et al. Validation of
National Institutes of Health global scoring system for chronic
graft-versus-host disease (GVHD) according to overall and GVHD-specific
survival. Biol Blood Marrow Transplant. 2014;20:556-63. |
|
|
|
|
|
37. Pidala J, Vogelsang G, Martin P, Chai X, Storer
B, Pavletic S, et al. Overlap subtype of chronic graft-versus-host disease is
associated with an adverse prognosis, functional impairment, and inferior patient-reported
outcomes: a Chronic Graft-versus-Host Disease Consortium study.
Haematologica. 2012;97:451-8. |
|
|
38. Palmason S, Marty FM, Treister NS. How do we
manage oral infections in allogeneic stem cell transplantation and other
severely immunocompromised patients?. Oral Maxillofac Surg Clin North Am.
2011;23:579-99, vii. |
|
|
39. Mawardi H, Elad S, Correa ME, Stevenson K, Woo
SB, Almazrooa S, et al. Oral epithelial dysplasia and squamous cell carcinoma
following allogeneic hematopoietic stem cell transplantation: clinical
presentation and treatment outcomes. Bone Marrow Transplant. 2011;46:884-91. |
|
|
40. Zadik Y, Zeevi I, Luboshitz-Shon N, Dakwar N,
Wolff A, Shapira MY, et al. Safety and efficacy of an intra-oral
electrostimulator for the relief of dry mouth in patients with chronic graft
versus host disease: Case Series. Med Oral Patol Oral Cir Bucal.
2014;19:e212-9. |
|